R&D Tax Credit Boosts $2.9M for Cyclacel Pharmaceuticals, Putting Them Ahead!
Cyclacel Pharmaceuticals Receives a £2.3 million R&D credit from HMRC Cyclacel Anticipates a $0.8 Million Increase Subject to Tax Credit Adjustment According to a Smart News report, a £2.3 million R&D tax credit from the UK government’s tax agency, HMRC, Cyclacel Pharmaceuticals (NASDAQ: CYCC) has revealed a notable improvement in its financials. This credit is … Read more